A Retrospective Assessment of Accelerated Guideline-Directed Medical Therapy for Heart Failure
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 342
- 试验地点
- 1
- 主要终点
- Number of Patients Receiving all Four Class I GDMT Drugs at Final Visit of Follow-up
研究概览
简要总结
The aim of the study was to evaluate the efficacy and safety of a Guideline-Directed Medical Therapy (GDMT) clinic within a general cardiology practice relative to usual care. This study analyzed data from patients with heart failure (HF) who were referred to the GDMT clinic at Massachusetts General Hospital (MGH). For the comparator arm, patients in the GDMT clinic were matched to data of patients contained within in the MGH Research Patient Data Repository (RPDR).
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
结局指标
主要结局
Number of Patients Receiving all Four Class I GDMT Drugs at Final Visit of Follow-up
时间窗: Up to approximately 16 weeks
Class I GDMT drugs included angiotensin receptor/neprilysin inhibitor (ARNI), evidence-based beta blocker (eBBB), mineralocorticoid receptor antagonist (MRA), sodium-glucose co-transporter-2 inhibitor (SGLT2i) or renin angiotensin system inhibitor (RASi), eBBB, MRA, SGLT2i.
次要结局
- Number Patients Receiving 50% or More of the Target Dose of Four Class I GDMT Drugs at Final Visit of Follow-up(Up to approximately 16 weeks)
- Number of Patients on a Higher Number of Therapies at Final Visit of Follow-up Compared to Baseline(Baseline and up to approximately 16 weeks)
- Change From Baseline in New York Heart Association (NYHA) Classification(Baseline and up to approximately 16 weeks)
- Change From Baseline in N-terminal pro B-type Natriuretic Peptide (NT-proBNP) Concentration(Baseline and up to approximately 16 weeks)
- Change From Baseline in Echocardiography Measurement: LVEF(Baseline and up to approximately 16 weeks)
- Change From Baseline in Echocardiography Measurement: Left Ventricular End-Diastolic Volume Index (LVEDVi)(Baseline and up to approximately 16 weeks)
- Change From Baseline in Echocardiography Measurement: Left Ventricular End-Systolic Volume Index (LVESVi)(Baseline and up to approximately 16 weeks)
- Change From Baseline in Echocardiography Measurement: Left Atrial Volume Index (LAVi)(Baseline and up to approximately 16 weeks)
- Change From Baseline in Echocardiography Measurement: Left Ventricular Mass Index (LVMi)(Baseline and up to approximately 16 weeks)